Effect of the duration of middle cerebral artery occlusion on the risk of hemorrhagic transformation after tissue plasminogen activator injection in rats

Brain Research

Volumn 1243, Issue , 2008, Pages 161-166

  Copin, Jean Christophe ^a,b   Gasche, Yvan ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Brain; Embolism; Hemorrhage; Rat; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE; HEMOGLOBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; HEMOGLOBIN DETERMINATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; NEUROLOGIC EXAMINATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECANALIZATION; RISK; STROKE;

ANIMALS; CEREBRAL ARTERIES; CEREBRAL HEMORRHAGE; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; HEMOGLOBINS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; RISK FACTORS; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

ANIMALIA; RATTUS;

EID: 55649096635     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.09.025     Document Type: Article

References (34)

1. Asahi M., Asahi K., Wang X., and Lo E.H. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 20 (2000) 452-457
2. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M.C., Davis R.L., and Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17 (1986) 472-476
3. Busch E., Kruger K., and Hossmann K.A. Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat. Brain Res. 778 (1997) 16-24
4. Castellanos M., Leira R., Serena J., Blanco M., Pedraza S., Castillo J., and Davalos A. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 35 (2004) 1671-1676
5. Castellanos M., Sobrino T., Millan M., Garcia M., Arenillas J., Nombela F., Brea D., Perez de la Ossa N., Serena J., Vivancos J., Castillo J., and Davalos A. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke. A Multicenter Confirmatory Study. Stroke 38 (2007) 1855-1859
6. Clark W.M., Wissman S., Albers G.W., Jhamandas J.H., Madden K.P., and Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. Jama 282 (1999) 2019-2026
7. Copin J.C., Merlani P., Sugawara T., Chan P.H., and Gasche Y. Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats. Exp. Neurol. 213 (2008) 196-201
8. del Zoppo G.J., Poeck K., Pessin M.S., Wolpert S.M., Furlan A.J., Ferbert A., Alberts M.J., Zivin J.A., Wechsler L., Busse O., et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann. Neurol. 32 (1992) 78-86
9. Fujimura M., Gasche Y., Morita-Fujimura Y., Massengale J., Kawase M., and Chan P.H. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res. 842 (1999) 92-100
10. Gasche Y., Fujimura M., Morita-Fujimura Y., Copin J.C., Kawase M., Massengale J., and Chan P.H. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J. Cereb. Blood Flow Metab. 19 (1999) 1020-1028
11. Gidday J.M., Gasche Y.G., Copin J.C., Shah A.R., Perez R.S., Shapiro S.D., Chan P.H., and Park T.S. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H558-H568
12. Hacke W., Kaste M., Fieschi C., von Kummer R., Davalos A., Meier D., Larrue V., Bluhmki E., Davis S., Donnan G., Schneider D., Diez-Tejedor E., and Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352 (1998) 1245-1251
13. Hacke W., Donnan G., Fieschi C., Kaste M., von Kummer R., Broderick J.P., Brott T., Frankel M., Grotta J.C., Haley Jr. E.C., Kwiatkowski T., Levine S.R., Lewandowski C., Lu M., Lyden P., Marler J.R., Patel S., Tilley B.C., Albers G., Bluhmki E., Wilhelm M., and Hamilton S. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
14. Hacke W., Albers G., Al-Rawi Y., Bogousslavsky J., Davalos A., Eliasziw M., Fischer M., Furlan A., Kaste M., Lees K.R., Soehngen M., and Warach S. The desmoteplase in acute ischemic stroke trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36 (2005) 66-73
15. Hamann G.F., Okada Y., Fitridge R., and del Zoppo G.J. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 26 (1995) 2120-2126
16. Kano T., Katayama Y., Tejima E., and Lo E.H. Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke. Brain Res. 854 (2000) 245-248
17. Kelly M.A., Shuaib A., and Todd K.G. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp. Neurol. 200 (2006) 38-49
18. Korninger C., and Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb. Haemost. 46 (1981) 561-565
19. Latour L.L., Kang D.W., Ezzeddine M.A., Chalela J.A., and Warach S. Early blood-brain barrier disruption in human focal brain ischemia. Ann. Neurol. 56 (2004) 468-477
20. Lyden P.D., Madden K.P., Clark W.M., Sasse K.C., and Zivin J.A. Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits. Stroke 21 (1990) 1589-1593
21. Murray C.J., and Lopez A.D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349 (1997) 1269-1276
22. Neumann-Haefelin C., Brinker G., Uhlenkuken U., Pillekamp F., Hossmann K.A., and Hoehn M. Prediction of hemorrhagic transformation after thrombolytic therapy of clot embolism: an MRI investigation in rat brain. Stroke 33 (2002) 1392-1398
23. NINDS-group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333 (1995) 1581-1587
24. Petty M.A., and Wettstein J.G. Elements of cerebral microvascular ischaemia. Brain Res. Brain Res. Rev. 36 (2001) 23-34
25. Rha J.H., and Saver J.L. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 38 (2007) 967-973
26. Rosell A., Ortega-Aznar A., Alvarez-Sabin J., Fernandez-Cadenas I., Ribo M., Molina C.A., Lo E.H., and Montaner J. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 37 (2006) 1399-1406
27. Rosenberg G.A. Matrix metalloproteinases in neuroinflammation. Glia 39 (2002) 279-291
28. Slivka A., and Pulsinelli W. Hemorrhagic complications of thrombolytic therapy in experimental stroke. Stroke 18 (1987) 1148-1156
29. Standefer J.C., and Vanderjagt D. Use of tetramethylbenzidine in plasma hemoglobin assay. Clin. Chem. 23 (1977) 749-751
30. Tejima E., Katayama Y., Suzuki Y., Kano T., and Lo E.H. Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model. Stroke 32 (2001) 1336-1340
31. Thomalla G., Sobesky J., Kohrmann M., Fiebach J.B., Fiehler J., Zaro Weber O., Kruetzelmann A., Kucinski T., Rosenkranz M., Rother J., and Schellinger P.D. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke 38 (2007) 313-318
32. von Kummer R., and Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 23 (1992) 646-652
33. Wang X., Tsuji K., Lee S.R., Ning M., Furie K.L., Buchan A.M., and Lo E.H. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 35 (2004) 2726-2730
34. Xi G., Keep R.F., and Hoff J.T. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 5 (2006) 53-63